IL281297B2 - Anti-NPR1 antibodies and their uses - Google Patents

Anti-NPR1 antibodies and their uses

Info

Publication number
IL281297B2
IL281297B2 IL281297A IL28129721A IL281297B2 IL 281297 B2 IL281297 B2 IL 281297B2 IL 281297 A IL281297 A IL 281297A IL 28129721 A IL28129721 A IL 28129721A IL 281297 B2 IL281297 B2 IL 281297B2
Authority
IL
Israel
Prior art keywords
seq
antibody
npr1
domain
comprises seq
Prior art date
Application number
IL281297A
Other languages
English (en)
Hebrew (he)
Other versions
IL281297B1 (en
IL281297A (en
Inventor
Jesper Gromada
Lori C Morton
Michael Dunn
Jia Su
Jason Mastaitis
Original Assignee
Regeneron Pharma
Jesper Gromada
Lori C Morton
Michael Dunn
Jia Su
Jason Mastaitis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Jesper Gromada, Lori C Morton, Michael Dunn, Jia Su, Jason Mastaitis filed Critical Regeneron Pharma
Publication of IL281297A publication Critical patent/IL281297A/en
Publication of IL281297B1 publication Critical patent/IL281297B1/en
Publication of IL281297B2 publication Critical patent/IL281297B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL281297A 2018-10-23 2019-10-18 Anti-NPR1 antibodies and their uses IL281297B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862749557P 2018-10-23 2018-10-23
US201862755720P 2018-11-05 2018-11-05
PCT/US2019/057033 WO2020086406A2 (en) 2018-10-23 2019-10-18 Anti-npr1 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
IL281297A IL281297A (en) 2021-04-29
IL281297B1 IL281297B1 (en) 2026-01-01
IL281297B2 true IL281297B2 (en) 2026-05-01

Family

ID=68732036

Family Applications (1)

Application Number Title Priority Date Filing Date
IL281297A IL281297B2 (en) 2018-10-23 2019-10-18 Anti-NPR1 antibodies and their uses

Country Status (16)

Country Link
US (4) US11306148B2 (enExample)
EP (1) EP3870612A2 (enExample)
JP (3) JP7439076B2 (enExample)
KR (1) KR20210082207A (enExample)
CN (1) CN112805303B (enExample)
AU (1) AU2019368196B2 (enExample)
CA (1) CA3115102A1 (enExample)
CL (3) CL2021000942A1 (enExample)
CO (1) CO2021006663A2 (enExample)
IL (1) IL281297B2 (enExample)
MX (2) MX2021004284A (enExample)
MY (1) MY205168A (enExample)
PH (1) PH12021550255A1 (enExample)
SG (1) SG11202101037QA (enExample)
WO (1) WO2020086406A2 (enExample)
ZA (1) ZA202100714B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3115102A1 (en) 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Anti-npr1 antibodies and uses thereof
PH12021553101A1 (en) 2019-06-12 2023-10-02 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
EP4259661A1 (en) 2020-12-14 2023-10-18 Novartis AG Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
US12325752B2 (en) 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists
WO2023009529A2 (en) 2021-07-28 2023-02-02 Trustees Of Boston University Novel polypeptides and uses thereof
US20240327539A1 (en) 2021-10-11 2024-10-03 Regeneron Pharmaceuticals, Inc. Methods of effecting a hemodynamic change by administering an anti-npr1 antibody
WO2023107957A1 (en) 2021-12-06 2023-06-15 Regeneron Pharmaceuticals, Inc. Antagonist anti-npr1 antibodies and methods of use thereof
JP2025510997A (ja) 2022-03-30 2025-04-15 ノバルティス アーゲー 抗ナトリウム利尿ペプチド受容体１（ｎｐｒ１）抗体を使用して障害を治療する方法
AU2024287056A1 (en) * 2023-06-08 2025-12-11 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-npr1 antibody and pharmaceutical use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120270923A1 (en) * 2011-03-17 2012-10-25 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
US20140343120A1 (en) * 2004-02-17 2014-11-20 University Of South Florida Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US20160168251A1 (en) * 2008-12-03 2016-06-16 Morphosys Ag Antibodies for guanylyl cyclase receptors
WO2016131943A1 (en) * 2015-02-20 2016-08-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US20100310561A1 (en) * 2007-06-06 2010-12-09 Boehringer Ingelheim International Gmbh Natriuretic fusion proteins
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
SG177640A1 (en) * 2009-07-13 2012-02-28 Genentech Inc Diagnostic methods and compositions for treatment of cancer
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
US9451770B2 (en) 2012-06-08 2016-09-27 Charles Despres Method of activating immune response in plants
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
WO2017209553A2 (ko) 2016-06-03 2017-12-07 사회복지법인 삼성생명공익재단 환자 유래 세포를 이용한 항체 스크리닝 방법
WO2018075792A1 (en) * 2016-10-20 2018-04-26 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
US20190135804A1 (en) 2017-11-03 2019-05-09 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Compositions and methods for the inhibition of pruritus
CA3115102A1 (en) 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Anti-npr1 antibodies and uses thereof
US12703762B2 (en) 2018-12-18 2026-08-11 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
PH12021553101A1 (en) 2019-06-12 2023-10-02 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
EP4259661A1 (en) 2020-12-14 2023-10-18 Novartis AG Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
US12325752B2 (en) 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists
WO2023107957A1 (en) 2021-12-06 2023-06-15 Regeneron Pharmaceuticals, Inc. Antagonist anti-npr1 antibodies and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140343120A1 (en) * 2004-02-17 2014-11-20 University Of South Florida Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US20160168251A1 (en) * 2008-12-03 2016-06-16 Morphosys Ag Antibodies for guanylyl cyclase receptors
US20120270923A1 (en) * 2011-03-17 2012-10-25 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
WO2016131943A1 (en) * 2015-02-20 2016-08-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LOWE D G ET AL,, HUMAN NATRIURETIC PEPTIDE RECEPTOR-A GUANYLYL CYCLASE. HORMONE CROSS-LINKING AND ANTIBODY REACTIVITY DISTINGUISH RECEPTOR GLYCOFORMS., 25 October 1992 (1992-10-25) *

Also Published As

Publication number Publication date
CL2021000942A1 (es) 2022-02-04
AU2019368196B2 (en) 2026-04-16
KR20210082207A (ko) 2021-07-02
US11306148B2 (en) 2022-04-19
BR112021004329A2 (pt) 2021-08-03
US11820826B2 (en) 2023-11-21
CO2021006663A2 (es) 2021-06-10
CL2023001377A1 (es) 2023-10-20
JP7439076B2 (ja) 2024-02-27
CL2024000378A1 (es) 2024-08-23
JP2025148445A (ja) 2025-10-07
MX2024011444A (es) 2024-09-25
NZ773064A (en) 2024-04-26
CN112805303A (zh) 2021-05-14
MX2021004284A (es) 2021-05-31
US20240309103A1 (en) 2024-09-19
US20200123263A1 (en) 2020-04-23
ZA202100714B (en) 2023-07-26
US20240059780A1 (en) 2024-02-22
CN112805303B (zh) 2024-08-20
AU2019368196A1 (en) 2021-03-18
MY205168A (en) 2024-10-04
WO2020086406A2 (en) 2020-04-30
JP2024056834A (ja) 2024-04-23
SG11202101037QA (en) 2021-02-25
IL281297B1 (en) 2026-01-01
IL281297A (en) 2021-04-29
JP7713051B2 (ja) 2025-07-24
WO2020086406A3 (en) 2020-06-04
EP3870612A2 (en) 2021-09-01
PH12021550255A1 (en) 2021-11-03
US20220204634A1 (en) 2022-06-30
JP2022505604A (ja) 2022-01-14
CA3115102A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
IL282968A (en) Anti-NKG2A antibodies and their use
IL276950A (en) Anti-CD73 antibodies and uses thereof
SG11202105885WA (en) Anti-claudin antibodies and uses thereof
IL274152B (en) Anti-galectin-9 antibodies and their uses
IL271477A (en) Anti-cd166 antibodies and their uses
IL275826A (en) Anti-mct1 antibodies and their uses
IL267942B (en) Anti-cd73 antibodies and uses thereof
IL268734A (en) Anti-LAG-3 antibodies and uses thereof
ZA202006066B (en) Anti-hla-g antibodies and use thereof
IL273157A (en) Antibodies specific to AXL and their uses
IL289585A (en) DLL3-targeted antibodies and uses thereof
SG11202009772PA (en) Anti-dll3 antibodies and uses thereof
IL291027A (en) Anti-steap1 antibodies and uses thereof
IL280321A (en) Antibodies against CXCR2 and their uses
IL276548A (en) Binding antibodies - BCMA and their uses
SG11202009625WA (en) Anti-trem-1 antibodies and uses thereof
SG11202105161YA (en) Anti-il-27 antibodies and uses thereof
IL281202A (en) Anti-TNFRSF9 antibodies and uses thereof
ZA202100714B (en) Anti-npr1 antibodies and uses thereof
IL277075A (en) Anti-PHF-tau antibodies and uses thereof
IL272476A (en) Anti-Apelin antibodies and their uses
IL277330A (en) Anti-IL-27 antibodies and uses thereof
SG11202012680TA (en) Anti-l1cam antibodies and uses thereof
GB201712032D0 (en) Antibodies and uses thereof
IL283926B1 (en) Antibodies against alpha-synuclein and their uses